Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY studyIbrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study, Published online: 02 February 2018; doi:10.1038/s41375-018-0023-2Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Source: Leukemia - February 2, 2018 Category: Hematology Authors: S Rule W Jurczak M Jerkeman C Rusconi M Trneny F Offner D Caballero C Joao M Witzens-Harig G Hess I Bence-Bruckler S-G Cho C Thieblemont W Zhou T Henninger J Goldberg J Vermeulen M Dreyling Source Type: research